Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top‐Selling Drugs
Medicare inflation rebates were not associated with smaller price increases among the top-selling drugs most affected by the policy. Additional measures are needed to prevent drug manufacturers from raising prices each year, such as extending inflation rebates to commercially insured patients.
Authors
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Benjamin N. Rome (ORCID: https://orcid.org/0000-0001-5776-3293)
- Alexander C. Egilman (ORCID: https://orcid.org/0000-0002-5343-4908)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
Publication Details
- Journal
- Health Services Research
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1111/1475-6773.70012
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Commonwealth Fund
- Arnold Ventures